Haemonetics Corp (HAE) Stock Price, Quote & News

Company Profile

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLy...

Industry: Medical Devices

Sector: Healthcare

Phone: 781 848 7100

Website: www.haemonetics.com

Address:

125 Summer Street, Boston, United States

OracleObelisk Feb. 4 at 9:31 AM

$HAE medical devices, plasma and blood management

0 · Reply

OfficialStocktwitsUser Feb. 4 at 2:01 AM

$HAE RSI: 4.62, MACD: -3.6222 Vol: 6.83, MA20: 73.00, MA50: 77.93 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

kb60521 Feb. 2 at 7:13 PM

$HAE Post earnings 70 is reasonable???

0 · Reply

Cutlass Jan. 22 at 7:57 PM

$HAE Will reload at the gap around 50.00 ✍️⏰

0 · Reply

ZacksResearch Jan. 15 at 4:21 PM

Is $HAE primed for growth or facing headwinds? 🤔 📈 Plasma & Hemostasis Management franchises show strong potential 📉 Dull macroeconomic scenario and fierce competition pose risks See what makes the investment case strong for $HAE 👉 https://www.zacks.com/stock/news/2818094/is-it-apt-to-retain-hae-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2818094-body-29092&ADID=SYND_STOCKTWITS_TWEET_2_2818094_BODY_29092

0 · Reply

ZacksResearch Jan. 15 at 3:21 PM

Is $HAE a hold… or a trap right now? ⚠️ Haemonetics’ plasma and hemostasis franchises are showing solid growth potential, but macro headwinds and rising competition are clouding the near-term outlook. See whether HAE still earns a spot in your portfolio 👉 https://www.zacks.com/stock/news/2818094/is-it-apt-to-retain-hae-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2818094-teaser-29090&ADID=SYND_STOCKTWITS_TWEET_2_2818094_TEASER_29090

0 · Reply

Pcocc Jan. 13 at 5:07 PM

$HAE why is this down today?

0 · Reply

smartkarma Jan. 12 at 6:03 PM

$HAE | Haemonetics Acquires Vivasure—Could This Be Its Next Growth Engine? "Haemonetics Corporation is making headlines with its recent strategic move to acquire Galway, Ireland-based Vivasure Medical—a developer of..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/haemonetics-acquires-vivasure-could-this-be-its-next-growth-engine

0 · Reply

TechridyStocks Jan. 7 at 5:08 PM

$HAE is now bullish over $83.18 I added.

0 · Reply

JarvisFlow Dec. 17 at 3:05 PM

Mizuho has adjusted their stance on Haemonetics ( $HAE ), setting the rating to Outperform with a target price of 75 → 90.

0 · Reply

Allspring Common Stock Fund Q4 2025 Performance Review

AAON ALNT BRKR CHWY EYE KEX RVLV

Jan 13, 2026, 12:46 PM EST - 21 days ago

Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:00 AM EST - 22 days ago

Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

OBIO

Jan 9, 2026, 8:00 AM EST - 25 days ago

Vivasure Medical Announces Acquisition by Haemonetics Corporation

Jan 9, 2026, 6:15 AM EST - 25 days ago

Haemonetics Acquires Vivasure Medical Limited

Jan 7, 2026, 6:17 PM EST - 27 days ago

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026

Jan 2, 2026, 6:00 AM EST - 4 weeks ago

Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 12:50 PM EST - 5 weeks ago

Earn Twice The Yield You Get From Bank On HAE Stock

Dec 2, 2025, 9:01 AM EST - 2 months ago

Top 2 Health Care Stocks You May Want To Dump This Month

EXAS

Nov 27, 2025, 9:30 AM EST - 2 months ago

Touchstone Small Company Fund Q3 2025 Performance Review

APLE CERT CIEN EME GPOR KLIC MMS

Nov 26, 2025, 1:09 PM EST - 2 months ago

Touchstone Small Cap Fund Q3 2025 Contributors And Detractors

AWI GHC IPAR NGVT WTM

Nov 7, 2025, 10:41 AM EST - 3 months ago

Haemonetics Is Still Undervalued, Even After The Rally

Nov 7, 2025, 7:25 AM EST - 3 months ago

The London Company Small Cap Q3 2025 Performance Update

AWI GHC IPAR NGVT WTM

Nov 7, 2025, 3:26 AM EST - 3 months ago

Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript

Nov 6, 2025, 6:00 AM EST - 3 months ago

Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Oct 30, 2025, 2:56 PM EDT - 3 months ago

Victory Sycamore Small Company Opportunity Fund Q3 2025 Top Contributors And Detractors

BOW ECG IPAR MRCY NATL SLGN SNDK

Oct 9, 2025, 4:05 PM EDT - 4 months ago

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025

Aug 11, 2025, 12:44 PM EDT - 6 months ago

I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)

Aug 9, 2025, 10:53 PM EDT - 6 months ago

Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript

Aug 8, 2025, 9:14 AM EDT - 6 months ago

These Analysts Slash Their Forecasts On Haemonetics After Q1 Results

Aug 7, 2025, 6:00 AM EDT - 6 months ago

Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

Jul 9, 2025, 4:05 PM EDT - 7 months ago

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

May 30, 2025, 6:00 AM EDT - 8 months ago

Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

May 10, 2025, 1:05 PM EDT - 9 months ago

Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript

May 8, 2025, 6:00 AM EDT - 9 months ago

Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Mar 31, 2025, 4:00 PM EDT - 11 months ago

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

Mar 3, 2025, 4:10 PM EST - 1 year ago

Haemonetics Announces Executive Leadership Updates

Feb 24, 2025, 6:00 AM EST - 1 year ago

Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference

Feb 6, 2025, 12:19 PM EST - 1 year ago

Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript

Feb 6, 2025, 6:00 AM EST - 1 year ago

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Jan 14, 2025, 6:13 AM EST - 1 year ago

Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A

Jan 8, 2025, 5:03 PM EST - 1 year ago

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025

Jan 6, 2025, 6:00 AM EST - 1 year ago

Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 1:16 AM EST - 1 year ago

Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A

Nov 9, 2024, 1:34 AM EST - 1 year ago

Haemonetics Corporation (HAE) Q2 2025 Earnings Call Transcript

Nov 7, 2024, 6:00 AM EST - 1 year ago

Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Oct 3, 2024, 4:05 PM EDT - 1 year ago

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024

Aug 16, 2024, 7:57 AM EDT - 1 year ago

Top 3 Health Care Stocks That Are Set To Fly This Quarter

IBRX PGNY

Aug 15, 2024, 6:30 AM EDT - 1 year ago

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Aug 8, 2024, 1:13 PM EDT - 1 year ago

Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript

Aug 8, 2024, 6:00 AM EDT - 1 year ago

Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Jul 30, 2024, 6:00 AM EDT - 1 year ago

Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire

Jul 8, 2024, 4:05 PM EDT - 1 year ago

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024

Jun 21, 2024, 3:50 PM EDT - 1 year ago

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Jun 18, 2024, 4:15 PM EDT - 1 year ago

Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

May 23, 2024, 6:00 AM EDT - 1 year ago

Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes

May 21, 2024, 4:05 PM EDT - 1 year ago

Haemonetics Announces Proposed Convertible Senior Notes Offering

May 10, 2024, 12:25 AM EDT - 1 year ago

Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript

May 9, 2024, 6:00 AM EDT - 1 year ago

Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Apr 10, 2024, 4:58 PM EDT - 1 year ago

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

OracleObelisk Feb. 4 at 9:31 AM

$HAE medical devices, plasma and blood management

0 · Reply

OfficialStocktwitsUser Feb. 4 at 2:01 AM

0 · Reply

kb60521 Feb. 2 at 7:13 PM

$HAE Post earnings 70 is reasonable???

0 · Reply

Cutlass Jan. 22 at 7:57 PM

$HAE Will reload at the gap around 50.00 ✍️⏰

0 · Reply

ZacksResearch Jan. 15 at 4:21 PM

0 · Reply

ZacksResearch Jan. 15 at 3:21 PM

0 · Reply

Pcocc Jan. 13 at 5:07 PM

$HAE why is this down today?

0 · Reply

smartkarma Jan. 12 at 6:03 PM

0 · Reply

TechridyStocks Jan. 7 at 5:08 PM

$HAE is now bullish over $83.18 I added.

0 · Reply

JarvisFlow Dec. 17 at 3:05 PM

Mizuho has adjusted their stance on Haemonetics ( $HAE ), setting the rating to Outperform with a target price of 75 → 90.

0 · Reply

JarvisFlow Dec. 15 at 6:10 PM

Baird updates rating for Haemonetics ( $HAE ) to Outperform, target set at 87 → 99.

0 · Reply

JarvisFlow Dec. 15 at 11:37 AM

Needham updates rating for Haemonetics ( $HAE ) to Hold.

0 · Reply

JarvisFlow Dec. 12 at 7:48 PM

JP Morgan has adjusted their stance on Haemonetics ( $HAE ), setting the rating to Neutral with a target price of 62 → 74.

0 · Reply

ZacksResearch Dec. 12 at 12:12 PM

HAE might be setting up for a quiet comeback — here’s what stands out. $HAE is seeing a Hospital rebound and rising NexSys PCS adoption, which boosts growth prospects even as FX and solvency pressures linger. That mix makes the hold-or-sell debate a lot more interesting right now. Full breakdown here 👉 https://www.zacks.com/stock/news/2803441/is-it-apt-to-retain-haemonetics-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2803441-teaser-24535&ADID=SYND_STOCKTWITS_TWEET_2_2803441_TEASER_24535

0 · Reply

ZacksResearch Dec. 12 at 11:12 AM

$HAE’s Hospital business is back on the growth track! 🚀 With a 5% revenue boost in the Hospital business and 12% sales growth in Blood Management Technologies, Haemonetics is positioned to capitalize on dynamic market conditions. However, watch out for foreign exchange impacts and solvency concerns. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2803441/is-it-apt-to-retain-haemonetics-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2803441-body-24534&ADID=SYND_STOCKTWITS_TWEET_2_2803441_BODY_24534

0 · Reply

JarvisFlow Dec. 11 at 1:55 PM

Citigroup updates rating for Haemonetics ( $HAE ) to Neutral, target set at 77 → 88.

0 · Reply

BillionerOfKing Dec. 10 at 7:57 PM

$HAE Current Stock Price: $86.67 Contracts to trade: $85 HAE Dec 19 2025 Call Entry: $0.15 Exit: $0.21 ROI: 42% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

stockanalysis_ Dec. 5 at 1:07 AM

Overbought Stocks: $MAGH $SND $HAE $EXAS $CDTX View the entire list here: https://stockanalysis.com/list/overbought-stocks/?ref=saveontrading

0 · Reply

Estimize Dec. 1 at 2:03 PM

Wall St is expecting 1.25 EPS for $HAE Q3 [Reporting 02/10 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont

0 · Reply

Cutlass Nov. 28 at 3:12 PM

$HAE Out for now - solid run from 48 💥

1 · Reply

Cutlass Nov. 25 at 3:37 PM

$HAE Trim a bit 81.25 and every dollar up 👀

0 · Reply

Cutlass Nov. 24 at 5:43 PM

$HAE Trim a tad at 80 🍎

0 · Reply

Market Cap	3.12B
Revenue (ttm)	1.36B
Net Income (ttm)	167.68M
EPS (ttm)	N/A
PE Ratio	13.74
Forward PE	13.38
Profit Margin	12.32%
Debt to Equity Ratio	1.08

Volume	765,400
Avg Vol	768,814
Day's Range	N/A - N/A
Shares Out	46.81M
Stochastic %K	5%
Beta	0.29
Analysts	Strong Sell
Price Target	$92.00